Literature DB >> 10922974

Smoking: a factor promoting onset and progression of diabetic nephropathy.

E Ritz1, H Ogata, S R Orth.   

Abstract

Although smoking was identified two decades ago as a factor promoting the onset and progression of nephropathy in Type 1 and then in Type 2 diabetes, its role has been largely neglected. More recently, it has been shown that smoking adversely affects renal haemodynamics and protein excretion even in subjects without renal disease. In addition, it impairs the prognosis for renal function in patients with non-diabetic renal disease. Recent studies have suggested the involvement of sympathetic activation, increased endothelin production, and impaired endothelial cell-dependent vasodilatation in the genesis of smoking-induced renal function impairement. Cessation of smoking apparently slows progression to renal failure, but the decision to stop smoking is difficult because of the high addictive potential of the habit. The challenge remains for diabetologists and nephrologists to motivate patients to stop smoking.

Entities:  

Mesh:

Year:  2000        PMID: 10922974

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  12 in total

Review 1.  Chronic renal disease.

Authors:  Malvinder S Parmar
Journal:  BMJ       Date:  2002-07-13

Review 2.  Smoking as a risk factor for diabetic nephropathy: a meta-analysis.

Authors:  Sensen Su; Wanning Wang; Tao Sun; Fuzhe Ma; Yue Wang; Jia Li; Zhonggao Xu
Journal:  Int Urol Nephrol       Date:  2017-06-19       Impact factor: 2.370

Review 3.  Update on blood pressure control and renal outcomes in diabetes mellitus.

Authors:  Mark Henry Joven; Robert J Anderson
Journal:  Curr Diab Rep       Date:  2015-07       Impact factor: 4.810

Review 4.  Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment.

Authors:  Olugbenga E Ayodele; C Olutayo Alebiosu; Babatunde L Salako
Journal:  J Natl Med Assoc       Date:  2004-11       Impact factor: 1.798

Review 5.  Diabetic nephropathy-pathophysiology and management.

Authors:  Judy Tan Shumway; Steven R Gambert
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 6.  Pathophysiology, prevention and management of chronic kidney disease in the hypertensive patient with diabetes mellitus.

Authors:  Anna Solini; Ele Ferrannini
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-04       Impact factor: 3.738

7.  Towards a rational screening strategy for albuminuria: results from the unreferred renal insufficiency trial.

Authors:  Arjan van der Tol; Wim Van Biesen; Francis Verbeke; Guy De Groote; Frans Vermeiren; Kathleen Eeckhaut; Raymond Vanholder
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

8.  Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.

Authors:  Kasper Broedbaek; Trine Henriksen; Allan Weimann; Morten Petersen; Jon T Andersen; Shoaib Afzal; Espen Jimenez-Solem; Frederik Persson; Hans-Henrik Parving; Peter Rossing; Henrik E Poulsen
Journal:  Diabetes Care       Date:  2011-03-31       Impact factor: 19.112

Review 9.  Proteinuria in diabetic nephropathy: treatment and evolution.

Authors:  Ruth C Campbell; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Curr Diab Rep       Date:  2003-12       Impact factor: 5.430

Review 10.  Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease.

Authors:  Robert D Toto
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.